SURGIMAB SAS

Their core work

SURGIMAB is a French medical technology SME based in Montpellier that develops diagnostic imaging and monitoring tools for cancer management. Their work is focused specifically on the clinical "watch and wait" approach to rectal cancer — building the tools and protocols that allow oncologists to actively surveil tumors rather than proceeding directly to surgery. They bring industry-side expertise in diagnostics and tool development into academic-led research consortia, translating clinical research into practical surveillance instruments. Their participation in both a doctoral training network and a staff exchange program signals a company invested in building the research ecosystem around their product niche.

What they specialise in

How they've shifted over time

SURGIMAB's keyword profile is identical across both projects — rectal cancer, active monitoring, surveillance, imaging, watch&wait, diagnostics, and tool development appear in both CAST (2019) and PRISAR2 (2020). There is no observable shift or expansion in their EU-funded focus, which reflects a company that entered the H2020 ecosystem with a fully formed specialization rather than one exploring new directions. The consistency is a signal of depth: they are not diversifying, they are doubling down on a single clinical problem domain.

SURGIMAB shows no keyword drift between their two projects, signaling deep specialization rather than portfolio diversification — future collaborators should expect a highly focused partner with specific oncology diagnostics expertise, not a generalist medical technology company.

How they like to work

SURGIMAB has taken participant roles in both projects and has never led a consortium as coordinator, which is typical for SMEs that contribute specialist technical expertise while academic institutions handle project governance. Their participation in both an MSCA-ITN doctoral training network (CAST) and an MSCA-RISE staff exchange program (PRISAR2) shows a preference for collaborative formats that involve researcher mobility and knowledge exchange. With 31 unique partners across 9 countries from just two projects, they operate within large, internationally diverse consortia — a strong indicator of their value as a specialist node in multi-partner networks.

Despite only two H2020 projects, SURGIMAB has connected with 31 unique consortium partners across 9 countries, a result of participation in large MSCA programs that typically involve broad international consortia. Their network is European in scope, consistent with the MSCA funding context.

What sets them apart

SURGIMAB occupies a narrow but high-value niche: a private SME bringing commercial diagnostics and tool development expertise to academic research on non-surgical rectal cancer management — a space where industry partners are rare. Their focus on watch-and-wait surveillance places them at the intersection of oncology, medical imaging, and clinical decision-making, which is attractive to consortia that need an industry partner to anchor translational work. For project coordinators building health research consortia, SURGIMAB offers a combination of SME status, clinical application focus, and MSCA track record that is difficult to replicate with a larger company.

Highlights from their portfolio

• CAST
  An MSCA-ITN doctoral training network on active cancer monitoring, indicating SURGIMAB's role in shaping early-career researcher training in their specific clinical domain.
• PRISAR2
  The sole project with confirmed EC funding (EUR 55,200), operating as an MSCA-RISE staff exchange program on proactive cancer monitoring — the project most directly linked to SURGIMAB's commercial diagnostics work.